On Feb. 23, the WHO told national vaccine regulatory agencies and pharmaceutical companies its recommendations for the viral composition of next season’s influenza vaccines.
A trivalent vaccine protects against three strains of the flu, including two influenza A strains and one influenza B strain. Last year, the WHO recommended quadrivalent shots.
For egg-based vaccines — which the CDC recently OK’d for people with egg allergies — the WHO suggests they target an A/Victoria/4897/2022 (H1N1)pdm09-like virus, an A/Thailand/8/2022 (H3N2)-like virus, and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
Cell-culture or recombinant-based vaccines are recommended to contain an A/Wisconsin/67/2022 (H1N1)pdm09-like virus, an A/Massachusetts/18/2022 (H3N2)-like virus, and a B/Austria/1359417/2021 (B/Victoria lineage)-like virus.
Quadrivalent vaccines for the 2024-25 Northern Hemisphere flu season are encouraged to also include a B/Phuket/3073/2013 (B/Yamagata lineage)-like virus.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
